Youth Cannabis Consumption continues to drop despite more legalization

When I was a teenager in the late 90s and early 2000s, you couldn’t escape the anti-drug messaging. It was everywhere – plastered across school hallways, embedded in our favorite cartoons, and drilled into our consciousness through endless PSAs. This was perhaps the height of the Drug War, where “Just Say No” wasn’t just a slogan, it was practically a religion.

I distinctly remember the dire warnings from authority figures about what would happen if we even thought about legalizing cannabis. “It would send the wrong message to the children!” they’d cry, clutching their D.A.R.E. pamphlets like precious pearls. The “What about the children?” argument became the prohibitionists’ favorite weapon, wielded with righteous fury against any suggestion of drug policy reform.

Fast forward to 2024, and we’re living in a vastly different landscape. Cannabis is legal in numerous states, available in sleek dispensaries rather than sketchy back alleys. And guess what? Those apocalyptic predictions about youth consumption skyrocketing? They didn’t just miss the mark – they got it completely backwards.

Recent research has revealed something fascinating: over the past decade, as more states have legalized cannabis, youth consumption has actually dropped significantly. That’s right – while adult use has reached historic highs (pun intended), fewer teenagers are experimenting with cannabis than during the height of prohibition.

Today, we’re going to dive deep into these findings and explore the possible reasons behind this counterintuitive trend. What changed? Why are kids today less interested in cannabis despite – or perhaps because of – its increasing legitimacy? The answers might surprise you, and they certainly offer some valuable lessons about drug policy, youth behavior, and the importance of honest, evidence-based approaches to public health.

Let’s unpack what the research tells us about youth cannabis consumption in the age of legalization, and why sometimes, the best way to protect our kids isn’t through fear and prohibition, but through regulation and honest dialogue.

A groundbreaking study published this month in Pediatric Reports has shattered the prohibitionist narrative about legalization and youth cannabis use. Drawing from the Centers for Disease Control and Prevention’s Youth Risk Behavior Survey, which polls high school students from grades 9-12, researchers uncovered a remarkable trend: cannabis use among teenagers has plummeted since 2011, even as more states embraced legalization.

The numbers tell a compelling story. In 2011, nearly 40% of adolescents reported having tried cannabis at least once. By 2021, that number had dropped to just 27.8%. Even more striking, regular use (defined as consumption within the past month) fell from 23.1% to 15.8% during the same period. Perhaps most encouragingly, early experimentation – trying cannabis before age 13 – dropped from 8.1% to 4.9%.

“The significant decreases observed in both the ‘ever used marijuana’ and ‘currently use marijuana’ categories highlight a promising reduction in adolescent marijuana use, with usage dropping to approximately 70% of the levels recorded in 2011,” the researchers noted.

This isn’t an isolated finding. A separate JAMA study published in April 2024 found no evidence that state-level legalization led to increased youth consumption. Washington State, one of the first to legalize recreational use, offers a particularly interesting case study. Their student surveys show that not only has youth cannabis use declined since legalization in 2012, but teenagers actually report that cannabis is harder to access now than during prohibition.

Similar trends have emerged north of the border. Canadian researchers found that high-school students reported more difficulty accessing cannabis after nationwide legalization in 2019, with current use rates dropping from 12.7% to 7.5% as retail sales expanded across the country.

Even federal officials have been forced to acknowledge these unexpected results. Marsha Lopez, chief of the National Institute on Drug Abuse’s epidemiological research branch, recently stated, “There have been no substantial increases at all. In fact, they have not reported an increase in perceived availability either, which is kind of interesting.”

Massachusetts provides another compelling example. A study of high school students there found that youth were no more likely to use cannabis after legalization, though they were more likely to perceive their parents as cannabis consumers – an interesting detail we’ll explore further when we examine the potential reasons behind these trends.

The evidence continues to mount. A NIDA-funded study published in the American Journal of Preventive Medicine found that “youth who spent more of their adolescence under legalization were no more or less likely to have used cannabis at age 15 years than adolescents who spent little or no time under legalization.”

All this comes at a time when adult cannabis use has reached “historic highs,” according to federal data. This stark contrast between rising adult use and declining youth consumption raises fascinating questions about how legalization might actually be helping to decrease teenage interest in cannabis – questions we’ll explore in detail in the next section.

As the data clearly shows, youth cannabis consumption is dropping significantly. But why? The answer lies in a perfect storm of social, economic, and cultural factors that have fundamentally altered how teenagers perceive and access cannabis.

Let’s start with the most obvious factor: regulated access. In legal markets, dispensaries have a powerful incentive to card their customers – their licenses and livelihoods depend on it. Unlike the street dealer who operates with impunity and gladly accepts cash from anyone willing to pay, legitimate cannabis businesses face severe consequences for selling to minors. Now, I have nothing against the small-time grower selling their homegrown stash to other consenting adults, but when we’re talking about organized crime networks controlling the black market, the dynamics become far more problematic.

But access is just part of the story. Perhaps more significant is the radical shift in how we educate young people about cannabis. Gone are the days of hyperbolic “scared straight” tactics that characterized my youth in the late 90s. Today’s drug education tends to focus on facts rather than fear, helping teenagers make informed decisions. This more honest approach, coupled with the “adult use” framing of legal cannabis, has effectively repositioned marijuana as something for grown-ups – like alcohol or tobacco.

Here’s where it gets really interesting: when I was a teenager, smoking weed was the ultimate act of rebellion. Nothing said “stick it to the man” quite like sparking up a joint. But in 2024, “the man” literally dispenses weed through corporate channels. For today’s contrarian teens, being “counter-culture” might actually mean being “counter-pot,” especially when it comes to big corporate cannabis. When something’s legal and commercialized, it loses that forbidden fruit appeal that made it so attractive to previous generations.

The role of technology can’t be overlooked either. Today’s teenagers have unprecedented access to entertainment and social connection through their devices. While my generation might have gathered in someone’s basement to smoke weed and listen to music, modern teens can immerse themselves in vast online worlds, connect with friends through social media, or lose themselves in endless streams of content – all without leaving their rooms.

Back in my day, the internet was just finding its footing. Sure, we had instant messaging and early social media, but it wasn’t the all-encompassing digital ecosystem that exists today. With fewer entertainment options, smoking weed with friends was often the default adventure. We’d get high and create our own fun, usually resulting in the kind of mischief that makes for great stories but questionable life choices.

The decline in youth cannabis use seems to stem from this perfect convergence of factors: better prevention education, regulated access that actually works, the loss of rebellious appeal, and the existence of countless alternative activities. One thing is crystal clear – legalization hasn’t increased youth consumption as prohibitionists predicted. If anything, it’s helped create an environment where fewer kids feel compelled to experiment with cannabis during their formative years.

SOURCE:

https://www.marijuanamoment.net/teen-marijuana-use-dropped-in-u-s-as-states

-enacted-legalization-new-study-using-federal-data-shows/

TEEN MARIJUANA DROPS WITH LEGALIZATION? READ ON…

TEEN MARIJUANA USE DROPS IN LEGAL STATES, HUH??

Last Thursday, we learned that the DEA’s marijuana rescheduling hearings are delayed until early next year. We also saw the list of 25 participants invited by the DEA to testify at those hearings. The takeaways here are: a) we will not have a substantive hearing on marijuana rescheduling until a new President takes office, and b) most of the hearing participants “represent law enforcement and anti-marijuana lobbies” as stated by MJBizDaily. Many people online didn’t like this at all, but I’ll humbly submit that it’s closer to a nothingburger.

The sky is not falling; delays are normal (and expected)

Anyone who has been around litigation or other court proceedings knows that delays are typical. You don’t have to be an administrative law expert (I’m not) to appreciate that. In this respect, it is puzzling why some of the industry folks, including cannabis lawyers, were howling at last Thursday’s news. It’s like complaining about the color of the sky.

Administrative Law Judge (ALJ) John Mulrooney’s Preliminary Order (“Order”) strikes me as a typical housekeeping exercise. He notes that the DEA hasn’t clarified which of the rescheduling hearing’s 25 participants support rescheduling, and which don’t. The Order gives a November 12 deadline (pretty tight!) for clarification on this point, and on related important issues– including disclosures of any known participant or DEA conflicts of interest. The Order also gives the DEA until November 12^th to designate its counsel of record.

The Order is also clear that the previously scheduled December 2^nd hearing remains on the docket. Participants must come prepared with “January-February 2025” dates for the big show. Lest you believe that the question of cannabis rescheduling will be fully and finally resolved at that time, I’m here to tell you otherwise. The hearings may drag on for any number of reasons, and once concluded, the ALJ will likely take his time arriving at a decision. Moreover, that decision could be litigated.

In short, people need to take a breather and understand that things are going as expected. Back on May 1, the day after the DEA agreed to initiate Schedule III rulemaking, I wrote that “I doubt cannabis will be on Schedule III” by Election Day. In the bigger picture, and long before that, I highlighted how Biden “passed the buck, putting us on an uncertain, circuitous path” by kicking off this rescheduling inquiry. For the 1,000^th time, Congress needs to act.

The participant list isn’t a huge deal; could even be helpful

The ALJ is presiding over a rulemaking process and making a record. A “record” in judicial proceedings is a technical term: it means the written account of all documents, evidence and proceedings in a matter. The record has already begun to accrete in this one, by way of the 42,925 comments on marijuana rescheduling submitted prior to the July 22 deadline (69.3% of them in support of rescheduling). The early 2025 hearings will continue to build out the record.

I mentioned above that the ALJ’s rulings may be litigated. If I were in the Judge’s chair, I’d make every possible effort to hear, on the record, from participants opposed to rescheduling. This is a useful way to insulate the Judge’s likely decision to follow the DEA’s Schedule III recommendation: all are fully and fairly heard.

No matter how much “evidence” or persuasive testimony opponents may conjure and enter into the record, it should not be enough to unseat the findings from FDA/HHS. That 250 page script considers the eight factors that determine control of a substance under 21 U.S.C. 811(c)– including that marijuana has a currently accepted medical use (CAMU). The report also contains favorable relative findings on abuse liability, with respect to other scheduled and unscheduled drugs (fentanyl, ketamine, alcohol, etc.). I just don’t see the naysayers getting there.

What’s next for marijuana rescheduling

Obviously, tomorrow’s elections are a pretty big deal. They don’t bear directly on these proceedings, but the composition of Congress and the Presidency for the next few years could potentially obviate the need for this rulemaking, or lessen its impact. Beyond that, a few interesting breadcrumbs may fall from the December 2^nd hearing, including which witnesses will testify on behalf of the 25 selected participants (a few are associations with yet-undesignated reps), whether any conflicts of interest arise, and anything else.

Stay tuned for December 2^nd if you’re a very process-oriented person. Everyone else can probably take a breather. This is what Biden signed us up for, after all, instead of following through with his campaign promises to decriminalize marijuana. (I couldn’t resist.)

For more on this topic, check out the following posts:

The cannabis Industry has undergone a remarkable transformation over the past few decades, evolving from a largely illegal substance to a multi-billion-dollar legal market in many regions. As this industry continues to expand, understanding the purchasing behaviors of different consumer segments becomes increasingly important. Two primary categories of cannabis consumers are medical users and recreational users, each with distinct motivations, preferences, and buying patterns. This article delves into the nuances of these purchasing behaviors, exploring why medical cannabis users tend to buy larger quantities while recreational consumers buy more frequently.

Understanding the Cannabis Market

The Rise of Medical Cannabis

Medical cannabis refers to the use of cannabis for therapeutic purposes, often prescribed to alleviate symptoms associated with various medical conditions. These can include chronic pain, anxiety, epilepsy, and multiple sclerosis, among others. As research continues to unveil the therapeutic benefits of cannabinoids like THC (tetrahydrocannabinol) and CBD (cannabidiol), more patients are turning to medical cannabis as an alternative or complement to traditional medications.

In many jurisdictions where cannabis has been legalized, patients must obtain a medical card or prescription from a licensed healthcare provider. This process not only legitimizes their use but also often provides access to higher-quality products and a wider range of options tailored for specific health needs.

The Growth of Recreational Cannabis

On the other hand, recreational cannabis is used primarily for enjoyment and relaxation rather than for medical reasons. With legalization sweeping across various states and countries, recreational users have access to a plethora of products designed for leisure consumption. This includes not just flower but also edibles, concentrates, and infused beverages.

Recreational consumers often seek out cannabis for its psychoactive effects, social experiences, or simply as a means to unwind after a long day. The motivations behind recreational use can vary widely—from social bonding and creativity enhancement to relaxation and stress relief.

Purchasing Patterns: A Comparative Analysis

Quantity vs. Frequency

One of the most significant distinctions between medical and recreational cannabis users lies in their purchasing patterns specifically, the quantity of product purchased per transaction versus the frequency of purchases.

Medical Cannabis Users: Larger Quantities

Medical cannabis users typically buy larger quantities during each transaction. This behavior can be attributed to several factors:

• Consistency in Treatment: Many medical users require consistent access to their medication to effectively manage chronic conditions. For instance, patients dealing with severe pain may need to consume cannabis daily or multiple times a day. Buying in bulk ensures they have enough supply on hand without frequent trips to dispensaries.
• Cost-Effectiveness: Purchasing larger quantities often leads to cost savings per unit. Medical users are often budget-conscious due to ongoing health expenses and may prefer buying in bulk to minimize costs over time.
• Product Variety: Medical users might also purchase various strains or products (e.g., tinctures, oils) that cater specifically to their health needs. This diversity allows them to experiment with different formulations until they find what works best for them.
• Legal Limitations: In some regions, legal restrictions dictate how much cannabis can be purchased at once. Medical users may maximize their allowable purchase limits during each visit.

Recreational Consumers: More Frequent Purchases

Conversely, recreational consumers tend to make more frequent purchases but buy smaller quantities each time. Several factors contribute to this behavior:

• Variety Seeking: Recreational users often enjoy experimenting with different strains and product types. Frequent purchases allow them to try new products regularly without committing to larger quantities that they may not enjoy.
• Social Consumption: Many recreational consumers use cannabis in social settings or during specific events (e.g., parties or gatherings). This leads them to buy smaller amounts that fit their immediate needs rather than stockpiling products.
• Changing Preferences: The preferences of recreational users can change frequently based on mood or occasion. They may opt for lighter strains during daytime activities and more potent options for evening relaxation, leading them to buy more often.
• Accessibility and Convenience: As dispensaries become more widespread and accessible, recreational consumers may find it easier to make spontaneous purchases rather than planning ahead for larger buys.

Motivations Behind Purchasing Behavior

Medical Users’ Motivations

The motivations behind medical cannabis purchases are deeply rooted in health concerns:

• Therapeutic Needs: Medical users prioritize finding products that effectively address their specific symptoms or conditions. Their purchasing decisions are often guided by recommendations from healthcare providers or peer-reviewed research.

• Reliability: Many medical consumers seek out brands known for their consistency in product quality and efficacy. Trust in the source is crucial; thus, they may develop loyalty toward certain dispensaries that meet their needs reliably.

• Education: Medical users often invest time in educating themselves about different cannabinoids and terpenes that may benefit their conditions. This knowledge influences their purchasing decisions significantly.

Recreational Users’ Motivations

Recreational consumers are driven by different motivations:

• Experience Seeking: Recreational users view cannabis as a means of enhancing experiences whether it’s enjoying music, art, or socializing with friends. Their purchases are often influenced by trends in consumption methods (like edibles or vape pens).

• Social Influence: Peer recommendations play a significant role in shaping recreational consumers’ choices. They may be swayed by what friends are using or what’s popular on social media platforms.

• Brand Loyalty: While brand loyalty exists among recreational users, it is often less pronounced than among medical users due to the wide variety of products available and the desire for novelty.

 Implications for Dispensaries and Brands

Understanding these purchasing behaviors has significant implications for dispensaries and brands operating within the cannabis market:

 Marketing Strategies

1. Targeted Promotions: Dispensaries can tailor promotions based on consumer segments offering bulk discounts for medical users while providing loyalty programs or limited-time offers for recreational consumers seeking variety.

1. Education Initiatives: Providing educational resources can help both consumer segments make informed decisions about their purchases—medical users may benefit from information on therapeutic benefits while recreational users might appreciate insights into new strains or consumption methods.

1. Product Diversity: Offering a wide range of products can cater to both segments effectively ensuring that medical users find what they need while also providing recreational consumers with exciting new options regularly.

Inventory Management

1. Stocking Strategies: Dispensaries should consider stocking larger quantities of popular medical products while maintaining a diverse array of smaller items aimed at recreational consumers who prefer variety.

1. Sales Forecasting: Understanding these purchasing patterns allows dispensaries to forecast sales more accurately—ensuring they have sufficient stock on hand during peak buying times.

Conclusion

The cannabis market is complex and multifaceted, shaped by diverse consumer needs and preferences. Medical cannabis users tend to purchase larger quantities due to their ongoing health requirements, while recreational consumers favor frequent smaller transactions driven by a desire for variety and experience.

As the industry continues to evolve, recognizing these distinct behaviors will be crucial for businesses aiming to thrive in this competitive landscape. By tailoring marketing strategies, product offerings, and educational initiatives accordingly, dispensaries can better serve both medical and recreational consumers alike—ultimately contributing to a more informed and satisfied customer base within the burgeoning world of legal cannabis.

CANNABIS PURCHASES WITH INFLATION, WHAT WE KNOW…

CONSUMERS CHOOSE QUANTITY OVER QUALITY WITH INFLATION!